Keros Therapeutics
Stock Forecast, Prediction & Price Target
Keros Therapeutics (KROS) stock Price Target by analysts
$103.5
Potential upside: 613.79%
Keros Therapeutics price prediction
What is Keros Therapeutics stock analysts` prediction?
Keros Therapeutics stock forecast: Based on 2 Wall Street analysts` predicted price targets for Keros Therapeutics in the last 3 months, the avarage price target is $103.5, with a high forecast of $NaN. The average price target represents a 613.79% change from the last price of $14.5.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Keros Therapeutics stock Price Target by analysts
Full breakdown of analysts given Keros Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Kelly Shi Jefferies | 0% 0/1 | 11 months ago | $107 637.93% upside | $62.02 | StreetInsider | Previous targets (0) |
Srikripa Devarakonda Truist Financial | 0% 0/1 | 11 months ago | $100 589.65% upside | $62.02 | StreetInsider | Previous targets (0) |
Vamil Divan Guggenheim | 0% 0/1 | about 1 year ago | $96 562.06% upside | $55.8 | StreetInsider | Previous targets (0) |
Joseph Catanzaro Piper Sandler | 0% 0/2 | over 1 year ago | $105 624.13% upside | $44.65 | StreetInsider | Previous targets (1) |
Unknown BTIG | N/A | almost 3 years ago | $105 624.13% upside | $49.98 | Benzinga | N/A |
Julian Harrison BTIG | 0% 0/1 | about 3 years ago | $80 451.72% upside | $31.79 | Pulse 2.0 | Previous targets (0) |
Joseph Catanzaro Piper Sandler | 0% 0/2 | over 3 years ago | $120 727.58% upside | $39.92 | TheFly | Previous targets (1) |
Keros Therapeutics Financial Estimates
Keros Therapeutics Revenue Estimates
Keros Therapeutics EBITDA Estimates
Keros Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $20.1M N/A | $0 -100% | $151K 0% | Avg: $5.68M Low: $5.06M High: $7.48M avg. 3664.17% | Avg: $30.48M Low: $27.14M High: $40.16M avg. 436.33% | Avg: $138.89M Low: $123.69M High: $182.97M avg. 355.60% | Avg: $313.05M Low: $278.80M High: $412.41M avg. 125.39% |
Net Income
% change YoY
| $-58.74M N/A | $-104.68M -78.19% | $-152.99M -46.15% | Avg: $-201.26M Low: $-194.35M High: $-133.98M avg. -31.54% | Avg: $-200.61M Low: $-223.50M High: $-60.95M avg. 0.32% | Avg: $-107.81M Low: $-152.29M High: $-92.47M avg. 46.25% | Avg: $-37.73M Low: $-53.30M High: $-32.36M avg. 65.00% |
EBITDA
% change YoY
| $-56.72M N/A | $-104.67M -84.52% | $-152.17M -45.37% | Avg: $-1.11M Low: $-1.46M High: $-991.86K avg. 99.26% | Avg: $-5.97M Low: $-7.86M High: $-5.31M avg. -436.33% | Avg: $-27.21M Low: $-35.85M High: $-24.23M avg. -355.60% | Avg: $-61.33M Low: $-80.80M High: $-54.62M avg. -125.39% |
EPS
% change YoY
| -$2.52 N/A | -$4.15 -64.68% | -$5.2 -25.30% | Avg: -$5.18 Low: -$6.6 High: -$4.55 avg. 0.44% | Avg: -$4.96 Low: -$7.59 High: -$2.07 avg. 4.20% | Avg: -$3.66 Low: -$5.17 High: -$3.14 avg. 26.16% | Avg: -$1.28 Low: -$1.81 High: -$1.1 avg. 65.00% |
Operating Expenses
% change YoY
| $76.47M N/A | $107.70M 40.84% | $170.09M 57.91% | Avg: $266.08M Low: $236.97M High: $350.53M avg. 56.43% | Avg: $1.42B Low: $1.27B High: $1.88B avg. 436.33% | Avg: $6.50B Low: $5.79B High: $8.56B avg. 355.60% | Avg: $14.65B Low: $13.05B High: $19.30B avg. 125.39% |
FAQ
What is Keros Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 20.00% in 2025-2028.
We have gathered data from 8 analysts. Their low estimate is -194.35M, average is -201.26M and high is -133.98M.
What is Keros Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 1145.37% in 2025-2028.
We have gathered data from 6 analysts. Their low revenue estimate is $5.06M, average is $5.68M and high is $7.48M.
What is Keros Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 23.95% in 2025-2028.
We have gathered data from 8 analysts. Their low earnings per share estimate is -$6.6, average is -$5.18 and high is $-4.55.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering Keros Therapeutics stock. The most successful analyst is Kelly Shi.